title: Expression of human aldo-keto reductase 1C2 in cell lines of peritoneal endometriosis: potential implications in metabolism of progesterone and dydrogesterone and inhibition by progestins.
abstract: The human aldo-keto reductase AKR1C2 converts 5α-dihydrotestosterone to the less active 3α-androstanediol and has a minor 20-ketosteroid reductase activity that metabolises progesterone to 20α-hydroxyprogesterone. AKR1C2 is expressed in different peripheral tissues, but its role in uterine diseases like endometriosis has not been studied in detail. Some progestins used for treatment of endometriosis inhibit AKR1C1 and AKR1C3, with unknown effects on AKR1C2. In this study we investigated expression of AKR1C2 in the model cell lines of peritoneal endometriosis, and examined the ability of recombinant AKR1C2 to metabolise progesterone and progestin dydrogesterone, as well as its potential inhibition by progestins. AKR1C2 is expressed in epithelial and stromal endometriotic cell lines at the mRNA level. The recombinant enzyme catalyses reduction of progesterone to 20α-hydroxyprogesterone with a 10-fold lower catalytic efficiency than the major 20-ketosteroid reductase, AKR1C1. AKR1C2 also metabolises progestin dydrogesterone to its 20α-dihydrodydrogesterone, with 8.6-fold higher catalytic efficiency than 5α-dihydrotestosterone. Among the progestins that are currently used for treatment of endometriosis, dydrogesterone, medroxyprogesterone acetate and 20α-dihydrodydrogesterone act as AKR1C2 inhibitors with low μM K(i) values in vitro. Their potential in vivo effects should be further studied.
authors.affiliation: Institute of Biochemistry, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
authors.forename: Nataša
authors.initials: N
authors.lastname: Beranič
authors.forename: Petra
authors.initials: P
authors.lastname: Brožič
authors.forename: Boris
authors.initials: B
authors.lastname: Brus
authors.forename: Izidor
authors.initials: I
authors.lastname: Sosič
authors.forename: Stanislav
authors.initials: S
authors.lastname: Gobec
authors.forename: Tea
authors.initials: T
authors.lastname: Lanišnik Rižner
mesh_terms: D020134:Catalytic Domain; D002460:Cell Line; D013196:Dihydrotestosterone / Q000378:metabolism; D004394:Dydrogesterone / Q000378:metabolism / Q000494:pharmacology*; D004715:Endometriosis / Q000378:metabolism* / Q000473:pathology; D005260:Female; D006801:Humans; D006913:Hydroxysteroid Dehydrogenases / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism*; D008958:Models, Molecular; D010537:Peritoneum / Q000378:metabolism* / Q000473:pathology; D011374:Progesterone / Q000378:metabolism*; D011372:Progestins / Q000378:metabolism / Q000494:pharmacology*; D045002:3-alpha-Hydroxysteroid Dehydrogenase (B-Specific)
chemical_list: D013196:Dihydrotestosterone; D004394:Dydrogesterone; D006913:Hydroxysteroid Dehydrogenases; D011374:Progesterone; D011372:Progestins; C435496:AKR1C2 protein, human; D045002:3-alpha-Hydroxysteroid Dehydrogenase (B-Specific)